Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 3
Abstract
Introduction. CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metabolic activity. Methods. We analyzed genetic variations in the promoter sequence of CYP2D6 gene for 71 hepatitis C negative and 15 hepatitis C positive subjects. Results. We found two novel genetic variants -1822A→G; -1740C→T, only in two patients with hepatitis C. Also, two linked new promoter sequence variations at –2060 G→A and –2053 T→G nucleotide positions that present in both hepatitis C negative and positive subjects are identified. The -2060 and -2053 variations are confirmed to be in linkage disequilibrium. The individuals with -2060A/A, and -2053G/G variation appeared to be associated with significantly lower levels of liver CYP2D6 mRNA. Analysis of CYP2D6 enzymatic activity in *1/*1 (wild type) subjects revealed that hepatitis C positive subjects expressed about 2.6-fold lower activity (24.0 ± 1.5 vs. 62.6 ± 3.7 pmol/min/mg; p = 0.0061) relative to hepatitis C negative. Conclusion. These data suggest that promoter variations -1822A→G and -1740C→T are present only in hepatitis C infected subjects. Hepatitis C positive individuals were associated with a lower liver CYP2D6 enzyme activity.This work was supported in part by National Institutes of Health Grants GM 62883, GM 32165, AI52663, AI 077390, HL 56548. RJYH was also supported by Milo Gibaldi Endowment. KVK was supported in part by NIH grant DK-02957
Authors and Affiliations
Martin T. Ho, Edward J. Kelly, Miklos Bodor, Tot Bui, Kris V. Kowdley, Rodney J. Y. Ho
Keywords
Related Articles
- EP ID EP78049
- DOI -
- Views 117
- Downloads 0
Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence
Hepatitis C virus (HCV) is a small, enveloped RNA virus. The number of HCV-infected individuals worldwide is estimated to be approximately 200 million. The vast majority of HCV infections persist, with up to 80% of all c...
Prevention of hepatocellular carcinoma
Because of its frequency and grave prognosis, preventing hepatocellular carcinoma is an urgent priority. Prevention should be possible because environmental carcinogens-chronic hepatitis B and C virus infections, dietary...
Multimodal therapy for hepatocellular carcinoma: A complementary approach to liver transplantation
Objective. To evaluate the survival benefit of multimodal therapy for the treatment of HCC. Background. Orthotopic liver transplantation (OLT) is considered the treatment of choice for selected patients with hepatocellul...
Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon-Ribavirin in daily practice
Background. Efficacy and safety of Pegylated Interferon alfa (PegIFN)-Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) in routine clinical practice seems to be comparable with results of randomizedcontrolle...
Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature
Recurrent hepatitis C virus (HCV) infection after liver transplantation is a significant cause of morbidity, mortality and graft loss. Spontaneous clearance of recurrent HCV after liver transplant is a rarely reported ph...